Xbrane Biopharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	127.24	-266.22	-388.17	-172.51	-188.38
Depreciation & Amortization	-	24.21	21.43	16.58	12.22
Other Operating Activities	-301.57	67.22	145.36	-7.25	-5.04
Change in Accounts Receivable	70.03	-4.56	-85.13	1.7	-61.09
Change in Inventory	48.98	-166	-56.6	-50.26	-
Change in Accounts Payable	-	212.82	22.57	-	-
Change in Other Net Operating Assets	-368.78	-	-	17.83	22.67
Operating Cash Flow	-250.69	-133.73	-406.68	-193.92	-219.61
Capital Expenditures	-	-0.5	-6.79	-11.62	-27.68
Sale (Purchase) of Intangibles	-139.64	-51.75	-9.98	-48.51	-49.67
Other Investing Activities	102.5	-	-	-	-
Investing Cash Flow	-37.14	-52.25	-16.77	-60.13	-77.35
Long-Term Debt Issued	77.6	70	225	-	-
Long-Term Debt Repaid	-47.78	-126.14	-34.74	-8.34	-7.27
Total Debt Repaid	-47.78	-126.14	-34.74	-8.34	-7.27
Net Debt Issued (Repaid)	29.82	-56.14	190.26	-8.34	-7.27
Issuance of Common Stock	240	337.24	120.02	170.55	380.87
Other Financing Activities	-14.22	-37.48	-11.58	-13.35	-24.23
Financing Cash Flow	255.61	243.62	298.7	148.86	349.37
Foreign Exchange Rate Adjustments	-6.05	0.84	-4.49	4.05	1.39
Miscellaneous Cash Flow Adjustments	0.53	0.44	0.64	-0.05	-1.76
Net Cash Flow	-37.74	58.93	-128.59	-101.19	52.04
Free Cash Flow	-250.69	-134.23	-413.47	-205.53	-247.29
Free Cash Flow Margin	-164.55%	-67.55%	-173.20%	-356.72%	-2309.16%
Free Cash Flow Per Share	-0.17	-13.64	-1800.48	-1004.76	-1310.16
Cash Interest Paid	-	17.65	7.58	2.59	2.64
Levered Free Cash Flow	-363.58	-67	-244	-169.78	-279.72
Unlevered Free Cash Flow	-353.78	-45.98	-232.43	-168.17	-278.07
Change in Working Capital	-249.77	42.27	-119.16	-30.73	-38.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.